Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 10

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 10
---
 (or approximately 19% in aggregate as of the date of the letter of intent) of the Company’s issued and outstanding common shares (the “Antev Transaction”). In addition to resale restrictions prescribed under applicable securities law, any shares issued to Antev shareholders will be subject to a 9-month staggered lock-up and an agreement granting certain voting rights in favor of management of the Company for 36 months. Antev shareholders will be entitled to receive up to $65 million in additional contingent consideration. The Antev Transaction is expected to close by the end of June 2025, subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the Antev Transaction will be consummated on the terms or timeframe currently contemplated, or at all.

Antev is developing Teverelix trifluoroacetate (“Teverelix”), a next generation GnRH antagonist, a potentially first in market product for high-risk prostate cancer patients and patients with first acute urinary retention (AUR) episodes due to enlarged prostate. Teverelix is a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions.

See “Risk Factors—We may not complete the Antev Transaction or may be delayed in completing the Antev Transaction.”

On May 22, 2025, the Company announced that it has received study may proceed approval from the United Arab Emirates Department of Health to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the skin.

On May 2, 2025, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Yorkville (as defined herein) in connection with the issuance and sale by the Company of debentures (the "Debentures") issuable in an aggregate principal amount of up to $5,000,000. Yorkville purchased and the Company issued a Debenture in the aggregate principal amount of $1,250,000 upon the signing of the Purchase Agreement, for net proceeds to the company of $1,125,000. An additional $